Augment Bone Graft - Bone matrix implant, artificial

País: Australia

Idioma: inglés

Fuente: Department of Health (Therapeutic Goods Administration)

Disponible desde:

Stryker Australia Pty Ltd

clase:

Class III

Fabricado por:

BioMimetic Therapeutics LLC 389-A Nichol Mill Lane, Franklin, TN, 37067 United States Of America

Área terapéutica:

17751 - Bone matrix implant, synthetic

indicaciones terapéuticas:

Beta-tricalcium phosphate provides a highly porous resorbable and osteoconductive scaffold that provides a framework for bone ingrowth, aids in preventing soft tissue infiltration and promotes stabilization of the blood clot. It is mixed with Recombinant human platelet-derived growth factor BB (rhPDGF-BB), prior to implantation which stimulates the recruitment and proliferation of a variety of cell types, including bone cells and mesenchymal stem cells, while also promoting revascularization. Augment Bone Graft is indicated for use as an alternative to autograft in hindfoot and ankle fusion procedures that require supplemental graft material, including tibiotalar, tibiocalcaneal, talonavicular and calcaneocuboid fusions.

Estado de Autorización:

A

Fecha de autorización:

2011-11-03